CARUMONAM IN THE SURGICAL FIELD

• Published in: CHEMOTHERAPY Vol. 35; no. Supplement2; pp. 496 - 503
• Main Authors: IWAI, SHIGETOMI, TAKAI, KAZUMITU, SATO, TAKESHI, MATSUSHITA, KANEAKI, KUNIMATSU, MASAHIKO, HORIKAWA, AKIRA, FURUHATA, HISASHI, KATO, KOUMEI, SATO, IZUMI, SAKAI, HIROKO, SAKABE, TAKASHI
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 1987
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.35.Supplement2_496

Basic and clinical studies on carumonam, a new monobactam antibiotic, were investigated and the following results were obtained. Antibacterial activities of carumonam against clinical isolates were compared with aztreonam (AZT), cefotetan (CTT), ticarcillin (TIPC) and mezlocillin (MZPC). Against clinical isolates such as Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Pseudomonas aeruginosa and Serratia marcescens, carumonam showed almost equal activity to AZT, but was more effective than other β-lactams against Gram-negative bacteria, including E. coli, K. pneumoniae, E. cloacae. It also demonstrated good activity against P. aeruginosa and excellent activity against S. marcescens. In clinical trials, it was administered i. v. by drip infusion to 11 patients with various surgical infections. The response was good in 5 cases, fair in 1 case and poor in 5 cases. In an evaluation of 7 cases of peritonitis, the result was good in 5 cases, fair in 1 and poor in 1 case. No serious side effects were noted.